| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Shugoshin-like 1; hSgo1; Serologically defined breast cancer antigen NY-BR-85; SGO1; |
| Entrez GeneID | 9540; |
| WB Predicted band size | 36kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide derived from internal of human QORX. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于QSOX(Quiescin Sulfhydryl Oxidase)抗体的文献参考(假设“QORX”可能存在拼写误差)，若需其他研究方向请进一步说明：
---
1. **文献名称**：*QSOX1 is essential for extracellular matrix stability and cancer metastasis*
**作者**：Ilani, T., et al.
**摘要**：研究揭示了QSOX1通过调控细胞外基质蛋白的氧化折叠，促进肿瘤细胞侵袭和转移的机制，并开发了特异性QSOX1抗体用于抑制实验。
2. **文献名称**：*Targeting QSOX1 in pancreatic ductal adenocarcinoma*
**作者**：Nguyen, H. C., et al.
**摘要**：利用QSOX1抗体阻断其在胰腺癌细胞中的活性，显著抑制肿瘤生长，提示其作为治疗靶点的潜力。
3. **文献名称**：*Structural and functional analysis of QSOX2 in neuronal development*
**作者**：Coppock, D. L., & Thorpe, C.
**摘要**：通过QSOX2抗体研究其在神经元突触形成中的作用，发现其调控硫醇氧化平衡对神经发育至关重要。
---
**注**：若您指的“QORX”为特定领域抗体(如某专利或新型靶点)，建议核实名称或补充关键词以便精准检索。
QORX antibody, often associated with QAX576 (a typographical variant or specific candidate name), refers to a class of investigational monoclonal antibodies targeting interleukin-4 receptor alpha (IL-4Rα), a key component in type 2 immune signaling pathways. Developed primarily for treating inflammatory and allergic disorders, these antibodies aim to block IL-4 and IL-13 cytokines, which drive conditions like asthma, atopic dermatitis, and chronic urticaria. The rationale stems from the role of IL-4Rα in mediating pro-inflammatory responses, including IgE production, eosinophil activation, and tissue remodeling.
QAX576. a notable example, was advanced by Novartis and tested in mid-phase clinical trials (Phase II) for asthma and eosinophilic esophagitis. Early data suggested potential efficacy in reducing exacerbations and improving lung function, though development status beyond these trials remains unclear. Such antibodies represent a shift toward precision biologics, offering targeted inhibition compared to broad immunosuppressants. Challenges include optimizing dosing, managing potential side effects (e.g., infections due to immunosuppression), and identifying patient subgroups with overactive type 2 inflammation. While not yet approved, QORX-related antibodies underscore the growing focus on cytokine-specific therapies in immunology.
×
